InsiderTrades.com logo
Global crypto currency reset (41 major banks signed up)
From Stansberry Research   |   Ad
Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...
 Here's everything you need to know.
Jeffery Kutok net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Jeffery Kutok Biography and Net Worth

Insider of Epizyme
Jeffery L. Kutok M.D. Ph.D. serves as Chief Scientific Officer of the Company. Dr. Kutok previously served as Chief Scientific Officer of Infinity Pharmaceuticals, Inc., or Infinity, a biotechnology company that develops cancer medication, from February 2017 to March 2020. Dr. Kutok previously served as Infinity’s Vice President of Biology and Translational Science from August 2013 to February 2017, and in other roles with increasing responsibility from January 2011 to August 2013. Prior to joining Infinity, Dr. Kutok was an associate professor of pathology at Harvard Medical School and Brigham and Women’s Hospital. Dr. Kutok’s laboratory focused on translational medicine research and biomarker identification in cancer, and he is an author on over 200 journal articles, reviews and book chapters. Dr. Kutok is board certified in Anatomic Pathology and Hematology and had clinical duties in Hematopathology and Molecular Diagnostics at Brigham and Women’s Hospital. Dr. Kutok received his B.S. in biology and his M.D., Ph.D. in medicine and molecular pathology from the State University of New York at Stony Brook. He was also a post-doctoral fellow at Harvard University in the laboratory of Dr. Gary Gilliland, M.D., Ph.D.

What is Jeffery Kutok's net worth?

The estimated net worth of Jeffery Kutok is at least $139,007.61 as of April 11th, 2022. Dr. Kutok owns 94,563 shares of Epizyme stock worth more than $139,008 as of April 23rd. This net worth evaluation does not reflect any other investments that Dr. Kutok may own. Additionally, Dr. Kutok receives a salary of $646,130.00 as Insider at Epizyme. Learn More about Jeffery Kutok's net worth.

How old is Jeffery Kutok?

Dr. Kutok is currently 55 years old. There are 5 older executives and no younger executives at Epizyme. The oldest executive at Epizyme is Mr. Grant C. Bogle, Pres, CEO, Principal Financial Officer & Director, who is 64 years old. Learn More on Jeffery Kutok's age.

What is Jeffery Kutok's salary?

As the Insider of Epizyme, Inc., Dr. Kutok earns $646,130.00 per year. The highest earning executive at Epizyme is Mr. Grant C. Bogle, Pres, CEO, Principal Financial Officer & Director, who commands a salary of $923,320.00 per year. Learn More on Jeffery Kutok's salary.

How do I contact Jeffery Kutok?

The corporate mailing address for Dr. Kutok and other Epizyme executives is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. Epizyme can also be reached via phone at (617) 229-5872 and via email at [email protected]. Learn More on Jeffery Kutok's contact information.

Has Jeffery Kutok been buying or selling shares of Epizyme?

Jeffery Kutok has not been actively trading shares of Epizyme during the past quarter. Most recently, Jeffery Kutok sold 2,741 shares of the business's stock in a transaction on Monday, April 11th. The shares were sold at an average price of $0.90, for a transaction totalling $2,466.90. Following the completion of the sale, the insider now directly owns 94,563 shares of the company's stock, valued at $85,106.70. Learn More on Jeffery Kutok's trading history.

Who are Epizyme's active insiders?

Epizyme's insider roster includes Shefali Agarwal (Insider), Robert Bazemore Jr. (CEO), Joseph Beaulieu (Insider), Jeffery Kutok (Insider), Pablo Legorreta (Director), and David Mott (Director). Learn More on Epizyme's active insiders.

Jeffery Kutok Insider Trading History at Epizyme

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/11/2022Sell2,741$0.90$2,466.9094,563View SEC Filing Icon  
4/5/2021Sell2,029$8.80$17,855.2054,028View SEC Filing Icon  
See Full Table

Jeffery Kutok Buying and Selling Activity at Epizyme

This chart shows Jeffery Kutok's buying and selling at Epizyme by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Epizyme Company Overview

Epizyme logo
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $1.47
Low: $1.47
High: $1.47

50 Day Range

MA: $1.47
Low: $1.47
High: $1.52

2 Week Range

Now: $1.47
Low: $0.41
High: $5.80

Volume

7,960 shs

Average Volume

3,225,203 shs

Market Capitalization

$247.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Global crypto currency reset (41 major banks signed up)
From Stansberry Research   |   Ad
Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...
 Here's everything you need to know.